0.387
price down icon1.78%   -0.007
after-market Dopo l'orario di chiusura: .39 0.003 +0.78%
loading
Precedente Chiudi:
$0.394
Aprire:
$0.381
Volume 24 ore:
67,835
Relative Volume:
0.13
Capitalizzazione di mercato:
$15.26M
Reddito:
-
Utile/perdita netta:
$-117.67M
Rapporto P/E:
-0.1252
EPS:
-3.09
Flusso di cassa netto:
$-101.06M
1 W Prestazione:
-2.15%
1M Prestazione:
+4.26%
6M Prestazione:
+3.48%
1 anno Prestazione:
-36.61%
Intervallo 1D:
Value
$0.3764
$0.3922
Intervallo di 1 settimana:
Value
$0.3711
$0.394
Portata 52W:
Value
$0.2195
$0.8264

Athira Pharma Inc Stock (ATHA) Company Profile

Name
Nome
Athira Pharma Inc
Name
Telefono
(425) 620-8501
Name
Indirizzo
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Name
Dipendente
26
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-07
Name
Ultimi documenti SEC
Name
ATHA's Discussions on Twitter

Confronta ATHA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ATHA
Athira Pharma Inc
0.387 15.26M 0 -117.67M -101.06M -3.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
396.93 102.81B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
453.54 58.59B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
567.22 61.25B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
733.66 43.23B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
318.73 36.53B 3.81B -644.79M -669.77M -6.24

Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-09-19 Downgrade Mizuho Outperform → Neutral
2024-09-04 Downgrade BTIG Research Buy → Neutral
2024-09-04 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2024-09-04 Downgrade Rodman & Renshaw Buy → Neutral
2024-08-19 Iniziato Rodman & Renshaw Buy
2022-10-17 Aggiornamento JMP Securities Mkt Perform → Mkt Outperform
2022-07-07 Iniziato Mizuho Buy
2022-06-23 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2022-06-23 Downgrade Jefferies Buy → Hold
2022-06-23 Downgrade Stifel Buy → Hold
2022-05-10 Iniziato BTIG Research Buy
2022-04-21 Iniziato Berenberg Buy
2021-12-15 Iniziato Goldman Neutral
2020-10-13 Iniziato Goldman Buy
2020-10-13 Iniziato JMP Securities Mkt Outperform
2020-10-13 Iniziato Jefferies Buy
2020-10-13 Iniziato Stifel Buy
Mostra tutto

Athira Pharma Inc Borsa (ATHA) Ultime notizie

pulisher
Sep 03, 2025

Visualizing Athira Pharma Inc. stock with heatmapsMarket Weekly Review & Daily Entry Point Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

What Fibonacci levels say about Athira Pharma Inc. reboundTrade Signal Summary & Daily Profit Maximizing Tips - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Is Athira Pharma Inc. forming a breakout patternMarket Trend Report & Weekly Setup with ROI Potential - khodrobank.com

Sep 03, 2025
pulisher
Sep 03, 2025

Does Athira Pharma Inc. stock benefit from AI growth2025 Trading Volume Trends & Real-Time Market Sentiment Reports - khodrobank.com

Sep 03, 2025
pulisher
Sep 03, 2025

Live market analysis of Athira Pharma Inc.2025 Geopolitical Influence & Accurate Buy Signal Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Using AI based signals to follow Athira Pharma Inc.Weekly Market Outlook & Free Weekly Watchlist of Top Performers - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Using data filters to optimize entry into Athira Pharma Inc.July 2025 PreEarnings & Long-Term Capital Growth Strategies - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Is Athira Pharma Inc. stock bottoming outEarnings Trend Report & Expert Approved Momentum Ideas - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Real time pattern detection on Athira Pharma Inc. stock2025 Volatility Report & Verified Entry Point Detection - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

What MACD signals say about Athira Pharma Inc.Dividend Hike & Intraday High Probability Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Is Athira Pharma Inc. stock reversal real or fakeJuly 2025 Review & Expert Approved Momentum Ideas - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

What machine learning models say about Athira Pharma Inc.Short Setup & Low Drawdown Momentum Ideas - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Using economic indicators to assess Athira Pharma Inc. potentialJuly 2025 Summary & Free Long-Term Investment Growth Plans - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Analyzing net buyer seller activity in Athira Pharma Inc.Gap Up & Breakout Confirmation Trade Signals - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Loss Report: Will Athira Pharma Inc. benefit from AI trendsProduct Launch & Detailed Earnings Play Alerts - khodrobank.com

Sep 03, 2025
pulisher
Sep 03, 2025

What’s next for Athira Pharma Inc. stock priceQuarterly Earnings Summary & Intraday High Probability Setup Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Can volume confirm reversal in Athira Pharma Inc.Weekly Trend Summary & Target Return Focused Picks - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Smart tools for monitoring Athira Pharma Inc.’s price action2025 Breakouts & Breakdowns & Weekly Chart Analysis and Trade Guides - Newser

Sep 03, 2025
pulisher
Sep 02, 2025

Price momentum metrics for Athira Pharma Inc. explainedMarket Risk Summary & Daily Profit Focused Stock Screening - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Leading vs lagging indicators on Athira Pharma Inc. performanceWeekly Investment Recap & Technical Pattern Based Signals - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Will Athira Pharma Inc. benefit from AI trendsJuly 2025 Setups & Verified Entry Point Detection - khodrobank.com

Sep 02, 2025
pulisher
Sep 02, 2025

Does Athira Pharma Inc. show high probability of rebound2025 Market Overview & Weekly Market Pulse Updates - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Athira Pharma (ATHA) Is Paying a $10M Settlement to Investors — Here’s How to Get Your Share - TradingView

Sep 02, 2025
pulisher
Sep 02, 2025

Will Athira Pharma Inc. benefit from macro trendsQuarterly Trade Review & Reliable Breakout Forecasts - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Is it too late to sell Athira Pharma Inc.Weekly Trade Report & Weekly Breakout Opportunity Watchlist - Newser

Sep 02, 2025
pulisher
Sep 01, 2025

Is Athira Pharma Inc.’s ROIC above industry averageEarnings Summary Report & Long-Term Growth Portfolio Plans - khodrobank.com

Sep 01, 2025
pulisher
Sep 01, 2025

Reversal Confirmed Athira Pharma Inc. Stock Rallies Above MAWeekly Profit Analysis & High Return Trade Opportunity Guides - beatles.ru

Sep 01, 2025
pulisher
Aug 31, 2025

Is Athira Pharma Inc. meeting your algorithmic filter criteriaMarket Sentiment Summary & Daily Profit Focused Screening - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

Technical Models Suggest Athira Pharma Inc. May Rebound SoonJuly 2025 Trade Ideas & Pattern Based Trade Signal System - beatles.ru

Aug 31, 2025
pulisher
Aug 31, 2025

Advanced analytics toolkit walkthrough for Athira Pharma Inc.July 2025 Breakouts & Weekly Watchlist of Top Performers - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

Applying Elliott Wave Theory to Athira Pharma Inc.2025 Pullback Review & Scalable Portfolio Growth Methods - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

How to monitor Athira Pharma Inc. with trend dashboardsMarket Risk Report & Smart Allocation Stock Tips - Newser

Aug 31, 2025

Athira Pharma Inc Azioni (ATHA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Athira Pharma Inc Azioni (ATHA) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER
Jul 01 '25
Sale
0.29
8,526
2,502
168,901
Litton Mark James
President and CEO
Jun 30 '25
Option Exercise
0.00
108,334
0
350,925
Litton Mark James
President and CEO
Jul 01 '25
Sale
0.29
25,123
7,374
325,802
San Martin Javier
CHIEF MEDICAL OFFICER
Jun 30 '25
Option Exercise
0.00
46,666
0
82,507
San Martin Javier
CHIEF MEDICAL OFFICER
Jul 01 '25
Sale
0.29
10,842
3,182
71,665
Worthington Mark
General Counsel and CCO
Jun 30 '25
Option Exercise
0.00
36,666
0
120,401
Worthington Mark
General Counsel and CCO
Jul 01 '25
Sale
0.29
8,526
2,502
111,875
Renninger Robert
SVP, Finance and Accounting
Jun 30 '25
Option Exercise
0.00
12,359
0
112,083
Renninger Robert
SVP, Finance and Accounting
Jul 01 '25
Sale
0.29
2,897
850
109,186
$85.44
price down icon 1.75%
$27.38
price up icon 1.11%
$23.80
price up icon 1.19%
$103.50
price up icon 3.07%
$142.53
price down icon 0.68%
biotechnology ONC
$318.73
price down icon 5.21%
Capitalizzazione:     |  Volume (24 ore):